While many observers focused on the effect the sale of its oncology business to Servier SA will have on Shire PLC, which is expecting a takeover offer from Takeda Pharmaceutical Co. Ltd., the deal is also a significant one for the privately held French group and its hopes to become a major player in cancer on both sides of the Atlantic. (Also see "Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray" - Scrip, 6 April, 2018.)
Servier is paying $2.4bn in cash for the unit, a price that is a little higher than analysts at Deutsche Bank and Jefferies had expected – the brokers had net present value (NPV) estimates of $2.1bn and $2.3bn respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?